Revvity unveils AI platform for molecular discovery
Revvity has announced the launch of Signals Xynthetica, a Models-as-a-Service AI platform designed to accelerate molecular and materials discovery by integrating computational design with experimental validation within a unified environment.
The platform, expected to launch in the first half of 2026, combines in-silico generation, predictive modelling, and experimental data within the Revvity Signals ecosystem, enabling scientific teams to iteratively design, test, and refine candidate molecules.
Bridging computational predictions with laboratory validation
Signals Xynthetica addresses a fundamental challenge in AI-driven discovery: the gap between powerful computational models and their practical application in laboratory workflows. The platform embeds predictive models directly into scientific contexts, connecting AI predictions with wet-laboratory outcomes to enable continuous learning and improvement.
“AI has enormous potential to transform how molecules and materials are designed, but that potential is only realised when models are connected to real scientific workflows and data,” said Kevin Willoe, president of Revvity Signals Software. “The Signals Xynthetica platform is about operationalising predictive science that brings in-silico design and experimental validation together in a continuous loop, accelerating discovery across industries.”
Models-as-a-Service delivery
The platform supports various in-silico design approaches, including de novo generation, property prediction, and multi-objective optimisation. Delivered as a Models-as-a-Service offering, it enables organisations to access and govern predictive models without maintaining complex AI infrastructure. Models can be applied consistently across projects, refreshed as new data emerges, and evaluated alongside experimental results.
Enterprise features and availability
Signals Xynthetica is designed to maintain strong governance, data stewardship, and scientific rigour whilst enabling customers to harness predictive capabilities at scale. The platform forms part of Revvity’s broader strategy for AI-augmented discovery across pharmaceutical, biotechnology, diagnostic laboratories, academia, and government sectors. Pre-registration for customers is currently underway, with early access programmes scheduled to begin in the first half of 2026.
For more information, visit: https://www.revvity.com
Digital issue: Please click here for more information
